These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 23887608

  • 1. Clinical features of recurrent Kawasaki disease and its risk factors.
    Yang HM, Du ZD, Fu PP.
    Eur J Pediatr; 2013 Dec; 172(12):1641-7. PubMed ID: 23887608
    [Abstract] [Full Text] [Related]

  • 2. [Association of liver damage with coronary artery lesion and no response to intravenous immunoglobulin in the acute stage of Kawasaki disease].
    Hu HM, Chen XZ, Zhang YL, DU ZD.
    Zhongguo Dang Dai Er Ke Za Zhi; 2022 Jun 15; 24(6):681-686. PubMed ID: 35762436
    [Abstract] [Full Text] [Related]

  • 3. Delayed intravenous immunoglobulin treatment increased the risk of coronary artery lesions in children with Kawasaki disease at different status.
    Qiu H, He Y, Rong X, Ren Y, Pan L, Chu M, Wu R, Shi H.
    Postgrad Med; 2018 May 15; 130(4):442-447. PubMed ID: 29745742
    [Abstract] [Full Text] [Related]

  • 4. [A retrospective analysis of 602 Kawasaki disease cases with electronic data capture system].
    Xie L, Zhou C, Wang R, Xiao T, Shen J, Huang M.
    Zhonghua Er Ke Za Zhi; 2015 Jan 15; 53(1):34-9. PubMed ID: 25748402
    [Abstract] [Full Text] [Related]

  • 5. Predictors of intravenous immunoglobulin resistance and coronary artery aneurysm in patients with Kawasaki disease.
    Chantasiriwan N, Silvilairat S, Makonkawkeyoon K, Pongprot Y, Sittiwangkul R.
    Paediatr Int Child Health; 2018 Aug 15; 38(3):209-212. PubMed ID: 29768976
    [Abstract] [Full Text] [Related]

  • 6. Evolution of laboratory values in patients with Kawasaki disease.
    Tremoulet AH, Jain S, Chandrasekar D, Sun X, Sato Y, Burns JC.
    Pediatr Infect Dis J; 2011 Dec 15; 30(12):1022-6. PubMed ID: 21817952
    [Abstract] [Full Text] [Related]

  • 7. [Therapeutic effectiveness of intravenous immunoglobulin at 1 g/kg and 2 g/kg on Kawasaki disease: a comparative and follow-up study].
    Qin LJ, Wang HW, Hu XF, Liu QJ, Shi H, Wei YX, Chen QJ, Cheng PX.
    Zhonghua Er Ke Za Zhi; 2006 Dec 15; 44(12):891-5. PubMed ID: 17254453
    [Abstract] [Full Text] [Related]

  • 8. Clinical relevance of the risk factors for coronary artery inflammation in Kawasaki disease.
    Honkanen VE, McCrindle BW, Laxer RM, Feldman BM, Schneider R, Silverman ED.
    Pediatr Cardiol; 2003 Dec 15; 24(2):122-6. PubMed ID: 12457252
    [Abstract] [Full Text] [Related]

  • 9. Risk factors and derived formosa score for intravenous immunoglobulin unresponsiveness in Taiwanese children with Kawasaki disease.
    Lin MT, Chang CH, Sun LC, Liu HM, Chang HW, Chen CA, Chiu SN, Lu CW, Chang LY, Wang JK, Wu MH.
    J Formos Med Assoc; 2016 May 15; 115(5):350-5. PubMed ID: 25910931
    [Abstract] [Full Text] [Related]

  • 10. Timing of intravenous immunoglobulin treatment and risk of coronary artery abnormalities in children with Kawasaki disease.
    Bal AK, Prasad D, Umali Pamintuan MA, Mammen-Prasad E, Petrova A.
    Pediatr Neonatol; 2014 Oct 15; 55(5):387-92. PubMed ID: 24636168
    [Abstract] [Full Text] [Related]

  • 11. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease.
    Tse SM, Silverman ED, McCrindle BW, Yeung RS.
    J Pediatr; 2002 Apr 15; 140(4):450-5. PubMed ID: 12006960
    [Abstract] [Full Text] [Related]

  • 12. Coronary artery status of patients with transient fever 24-36 h after first IVIG infusion did not differ from that seen in responsive patients.
    Baek JS, Yu JJ, Kim MJ, You J, Jun HO, Kim YH, Ko JK.
    Pediatr Rheumatol Online J; 2018 Dec 29; 16(1):83. PubMed ID: 30594188
    [Abstract] [Full Text] [Related]

  • 13. Common variants in the CRP promoter are associated with a high C-reactive protein level in Kawasaki disease.
    Kim JJ, Yun SW, Yu JJ, Yoon KL, Lee KY, Kil HR, Kim GB, Han MK, Song MS, Lee HD, Byeon JH, Sohn S, Hong YM, Jang GY, Lee JK, Korean Kawasaki Disease Genetics Consortium.
    Pediatr Cardiol; 2015 Feb 29; 36(2):438-44. PubMed ID: 25266886
    [Abstract] [Full Text] [Related]

  • 14. Risk factors for coronary artery lesions in children with Kawasaki disease.
    Duan J, Jiang H, Lu M.
    Arch Argent Pediatr; 2020 Oct 29; 118(5):327-331. PubMed ID: 32924395
    [Abstract] [Full Text] [Related]

  • 15. Increased Pentraxin 3 Levels Correlate With IVIG Responsiveness and Coronary Artery Aneurysm Formation in Kawasaki Disease.
    Kitoh T, Ohara T, Muto T, Okumura A, Baba R, Koizumi Y, Yamagishi Y, Mikamo H, Daigo K, Hamakubo T.
    Front Immunol; 2021 Oct 29; 12():624802. PubMed ID: 33912155
    [Abstract] [Full Text] [Related]

  • 16. Clinical indicators combined with S100A12/TLR2 signaling molecules to establish a new scoring model for coronary artery lesions in Kawasaki disease.
    Wu Y, Wang S, Zhou Y, Yang Y, Li S, Yin W, Ding Y.
    PLoS One; 2023 Oct 29; 18(10):e0292653. PubMed ID: 37824465
    [Abstract] [Full Text] [Related]

  • 17. Recurrent Kawasaki disease at a tertiary care center in Chandigarh, North West India: 24 years of clinical experience.
    Guleria S, Pilania RK, Jindal AK, Bhattarai D, Suri D, Singh S.
    Int J Rheum Dis; 2019 Jul 29; 22(7):1183-1187. PubMed ID: 30829007
    [Abstract] [Full Text] [Related]

  • 18. Infliximab Plus Intravenous Immunoglobulin (IVIG) Versus IVIG Alone as Initial Therapy in Children With Kawasaki Disease Presenting With Coronary Artery Lesions: Is Dual Therapy More Effective?
    Jone PN, Anderson MS, Mulvahill MJ, Heizer H, Glodé MP, Dominguez SR.
    Pediatr Infect Dis J; 2018 Oct 29; 37(10):976-980. PubMed ID: 29461447
    [Abstract] [Full Text] [Related]

  • 19. Relationship between ocular manifestations, laboratory findings, echocardiographic findings, and intravenous immunoglobulin resistance in Kawasaki disease.
    Jari M, Esmaeili H.
    Pediatr Rheumatol Online J; 2024 May 01; 22(1):50. PubMed ID: 38693550
    [Abstract] [Full Text] [Related]

  • 20. Comparison of Risk of Recrudescent Fever in Children With Kawasaki Disease Treated With Intravenous Immunoglobulin and Low-Dose vs High-Dose Aspirin.
    Platt B, Belarski E, Manaloor J, Ofner S, Carroll AE, John CC, Wood JB.
    JAMA Netw Open; 2020 Jan 03; 3(1):e1918565. PubMed ID: 31899532
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.